Treatment of Hepatocellular Carcinoma by Intraarterial Injection of Adriamycin/Mitomycin C Oil Suspension (ADMOS) Alone or Combined with CIS-Diaminodichloroplatinum (CDDP)

Abstract

We evaluated the effects of intraarterial injection of Adriamycin/ Mitomycin Coil (Lipiodol) suspension (ADMOS) alone and ADMOS+cis-diaminodichloroplatinum (CDDP) in 135 patients with hepatocellular carcinoma (HCC). A total of 59 patients received ADMOS alone and 76 patients received ADMOS+CDDP (ADMOS/CDDP). Tumor size was reduced by over 25% in 13 (34%) of the evaluable 38 patients in the ADMOS-alone group and in 39 (51%) of the 76 evaluable patients in the ADMOS/CDDP group. Serum alpha-fetoprotein (AFP) levels decreased by more than 50% in 10 (59%) of 17 ADMOS-alone patients and in 23 (70%) of 33 ADMOS/CDDP patients whose pretreatment AFP levels were above 0.2 mg/I. The overall one-and 2-year survival rates were 68% and 41%, respectively. No severe complications and no significant changes in laboratory values were observed, except for one patient in the ADMOS/CDDP group who developed a liver abscess. Although the tumor response was significantly better in patients treated by ADMOS/CDDP than in those treated by ADMOS-alone (p<0.05), there was no significant difference in the survival rates between the 2 groups. The intraarterial injection of ADMOS and CDDP was concluded to be effective in treating HCC judging by tumor response.

Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma

“…Recently, lipiodol has been used as a carrier of anticancer drugs, such as Adriamycin [30], cisplatin [31], epirubicin [32], mitoxantrone [33] and combinations [34,35]. However, there have been few randomized control studies which show the most effective anticancer drug or regimen.…”

Embolization of the hepatic falciform artery to prevent supraumbilical skin rash during transcatheter arterial chemoembolization for hepatocellular carcinoma

“…Interventions for managing hepatocellular carcinoma (HCC) have advanced considerably with transcatheter arterial chemoembolization (TACE) [1,2]. With the widespread use of TACE, various complications have been reported [3][4][5].…”